ArticleEuropean journal of nutrition2017
Ellagic acid in Emblica officinalis exerts anti-diabetic activity through the action on β-cells of pancreas.
Article in European journal of nutrition, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 2 syntheses or guidelines pooled it, 147 citations in OpenAlex.
- Ellagic acid as potential therapeutic compound for diabetes and its complications: a systematic review from bench to bed.Naunyn-Schmiedeberg's archives of pharmacology · 2024Pooled it
- Potential effect of tropical fruits Phyllanthus emblica L. for the prevention and management of type 2 diabetic complications: a systematic review of recent advances.European journal of nutrition · 2021Pooled it
- Targeted Regulation of Pancreatic Islet Function by Natural Products Against Type 2 Diabetes Mellitus: Advances and Prospects.Biomolecules · 2026Review
- Comprehensive Metabolite Profiling and Enzyme Inhibitory Potential of Psidium guajava L. Hydro Alcoholic Extract: An In vitro and In Silico Approach.Chemistry & biodiversity · 2026Article
- Unravelling the role of natural herbs for the management of diabetes mellitus.Diabetology & metabolic syndrome · 2025Review
- A Comprehensive Review of the Effects ofPreventive nutrition and food science · 2025Review
- Therapeutic Potential of Ellagic Acid in Liver Diseases.Molecules (Basel, Switzerland) · 2025Review
- Phenolic Acids from Fruit By-Products as Therapeutic Agents for Metabolic Syndrome: A Review.International journal of molecular sciences · 2025Review
- Edible Berries-An Update on Nutritional Composition and Health Benefits-Part II.Current nutrition reports · 2025Review
- Dietary polyphenols and human health: sources, biological activities, nutritional and immunological aspects, and bioavailability- a comprehensive review.Frontiers in immunology · 2025Review
- Plant-Based Diets and Phytochemicals in the Management of Diabetes Mellitus and Prevention of Its Complications: A Review.Nutrients · 2024Review
- Polyphenols: Secondary Metabolites with a Biological Impression.Nutrients · 2024Review
- Arazá:Foods (Basel, Switzerland) · 2024Review
- Exploring Folklore Ecuadorian Medicinal Plants and Their Bioactive Components Focusing on Antidiabetic Potential: An Overview.Plants (Basel, Switzerland) · 2024Review
- Coconut (Plants (Basel, Switzerland) · 2024Article
- Evaluation of phytochemical profile, and antioxidant, antidiabetic activities of indigenous Thai fruits.PeerJ · 2024Article
- TheCurrent topics in medicinal chemistry · 2024Review
- Overview of Natural Supplements for the Management of Diabetes and Obesity.Current diabetes reviews · 2024Review
- The emerging role of medical foods and therapeutic potential of medical food-derived exosomes.Nanoscale advances · 2023Review
- Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe present study was undertaken to explore the possible anti-diabetic mechanism(s) of Emblica officinalis (EO) and its active constituent, ellagic acid (EA), in vitro and in vivo.
methodNeonatal streptozotocin-induced non-obese type 2 diabetic rats were treated with a methanolic extract of EO (250 or 500 mg/kg) for 28 days, and blood glucose, serum insulin, and plasma antioxidant status were measured. Insulin and glucagon immunostaining and morphometry were performed in pancreatic section, and liver TBARS and GSH levels were measured. Additionally, EA was tested for glucose-stimulated insulin secretion and glucose tolerance test.
resultsTreatment with EO extract resulted in a significant decrease in the fasting blood glucose in a dose- and time-dependent manner in the diabetic rats. It significantly increased serum insulin in the diabetic rats in a dose-dependent manner. Insulin-to-glucose ratio was also increased by EO treatment. Immunostaining of pancreas showed that EO
conclusionEllagic acid in EO exerts anti-diabetic activity through the action on β-cells of pancreas that stimulates insulin secretion and decreases glucose intolerance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.